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Tumorigenesis and Neoplastic Progression
High-Density Gene Expression Analysis of
Tumor-Associated Macrophages from Mouse
Mammary Tumors
Laureen S. Ojalvo,* William King,† Dianne Cox,‡
and Jeffrey W. Pollard*
From the Department of Developmental and Molecular Biology,*
the Flow Cytometry Core Facility,† and the Department of
Anatomy and Structural Biology,‡ Albert Einstein College of
Medicine, Bronx, New York
Clinical and experimental evidence indicates that tu-
mor-associated macrophages (TAMs) promote malig-
nant progression. In breast cancer, TAMs enhance
tumor angiogenesis, tumor cell invasion, matrix re-
modeling, and immune suppression against the tu-
mor. In this study, we examined late-stage mammary
tumors from a transgenic mouse model of breast can-
cer. We used flow cytometry under conditions that
minimized gene expression changes to isolate a rig-
orously defined TAM population previously shown to
be associated with invasive carcinoma cells. The gene
expression signature of this population was com-
pared with a similar population derived from spleens
of non-tumor-bearing mice using high-density oligo-
nucleotide arrays. Using stringent selection criteria,
transcript abundance of 460 genes was shown to be
differentially regulated between the two populations.
Bioinformatic analyses of known functions of these
genes indicated that formerly ascribed TAM func-
tions, including suppression of immune activation
and matrix remodeling, as well as multiple mediators
of tumor angiogenesis, were elevated in TAMs. Fur-
ther bioinformatic analyses confirmed that a pure
and valid TAM gene expression signature in mouse
tumors could be used to assess expression of TAMs in
human breast cancer. The data derived from these
more physiologically relevant autochthonous tumors
compared with previous studies in tumor xenografts
suggest tactics by which TAMs may regulate tumor an-
giogenesis and thus provide a basis for exploring other
transcriptional mediators of TAM trophic functions
within the tumor microenvironment. (Am J Pathol
2009, 174:1048–1064; DOI: 10.2353/ajpath.2009.080676)
In many human cancers, a high density of tumor associ-
ated macrophages (TAMs) correlates with poor progno-
sis.1 This is particularly true in breast cancer where the
greatest numbers of studies have been performed.2 The
overexpression of macrophage growth factors and che-
moattractants similarly correlates with poor prognosis. In
human studies, overexpression of the primary macrophage
growth, proliferation and differentiation factor, colony-stim-
ulating factor-1 (CSF-1) correlates with poor prognosis in
ovarian, breast and endometrial cancer, among others.3–6
CCL2 (MCP-1) is another example of a macrophage che-
mokine that is over-expressed in breast tumors7,8 and
whose expression correlates with accumulation of TAM and
significantly poorer prognosis.9 Taken together, these hu-
man studies illustrate the active recruitment of macro-
phages to a growing tumor, and furthermore suggest that in
breast cancer, the presence of a high density of these
TAMs facilitate tumor progression to malignancy.
Experimental studies in mouse models of breast can-
cer performed by our laboratory and others have pro-
vided support for this conclusion. One model in which the
polyoma middle T (PyMT) oncoprotein is expressed in the
mammary epithelium directed by the mouse mammary
tumor virus (MMTV) long terminal repeat is a reliable
mouse model for human breast cancer. These animals
demonstrate spontaneous hyperplastic lesions at around
8 weeks of age that progress to late-stage metastatic
malignancy through numerous stages reminiscent of hu-
man mammary adenocarcinoma.10 When these mice
were crossed to mice lacking CSF-1 (Csf1op/op) the re-
sulting female offspring displayed severely diminished
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macrophage recruitment to tumors, and progression to
late-stage malignancy was significantly delayed with me-
tastasis dramatically reduced.11 Restoration of CSF-1 to
the mammary fat pad restored tumor progression and
metastatic capability. It has been further elaborated that
restoration of the pro-angiogenic factor, vascular endothe-
lial growth factor (VEGF)-A to the tumor microenvironment in
these macrophage-depleted animals restores tumor pro-
gression12 suggesting one mechanism by which TAMs fa-
cilitate tumor progression: through regulation of tumor an-
giogenesis.13 Similarly, depletion of CSF-1 or CSF-1
receptor signaling in host macrophages reduced tumor
growth in a xenograft model of human breast cancer and
this was associated with reduced angiogenesis.14
Animal models have revealed further insight into func-
tional mechanisms by which macrophages promote tu-
mor progression. At least six traits have been identified
that macrophages can confer on tumors that promote
their progression to malignancy.15 For example in addi-
tion to tumor angiogenesis as mentioned above, it is
known that macrophages are potent sources of metallo-
proteases that aid in matrix degradation16 and can facil-
itate efficient intravasation of carcinoma cells from a pri-
mary tumor into the surrounding stroma. Furthermore,
macrophages can induce tumor cell migration through
the stroma and enhance intravasation via the production
of growth factors such as epidermal growth factor (EGF)
in a reciprocal chemotactic loop with tumor-produced
CSF-117,18 or via the production of Wnt ligands.19 It is
speculated that these tissue trophic functions of TAMs
may recapitulate functions of macrophages during devel-
opment, such as regulation of epithelial cell movement in
terminal end buds during mammary gland develop-
ment.20,21 This contrasts with the classical view that mac-
rophages are critical mediators of innate immunity by
phagocytosing pathogens that are harmful to the host,
and promoting adaptive immunity through antigen pre-
sentation, giving them the capability to reject tumors
expressing foreign antigens. However, it is now under-
stood that in the tumor microenvironment, TAMs exhibit
decreased capacity to facilitate carcinoma cell killing and
inhibit adaptive immune responses, a process that allows
the tumor to evade T-cell mediated tumoricidal activity.22,23
In recognition of the number of functions attributed to
the TAM that can result in tumor promotion plus the
apparent ability of the tumor microenvironment to edu-
cate the macrophages to have functions that enhance
tumor survival and growth,24 the goal of this study has
been to use high density gene expression arrays to pro-
file TAMs from the late stage primary mammary tumors
from the PyMT mouse model of breast cancer to define a
transcriptome that could confer these functions. A rigor-
ous definition of our isolated macrophage population,
paired with methods to minimize perturbations in gene
expression, ensured the transcriptome defined was rep-
resentative of TAMs. This TAM population was then com-
pared with a classical “immune” population with the same
characteristics isolated from spleens of non-tumor bear-
ing mice. Various bioinformatic approaches revealed a
transcriptome that emphasized tissue trophic functions
and particularly angiogenic mediators. We hypothesize
that the data from these microarrays can be further ex-
plored for novel therapeutic targets against many other
tumor-promoting activities of TAMs.
Materials and Methods
Mice
All procedures involving mice were conducted in accor-
dance with National Institutes of Health regulations con-
cerning the use and care of experimental animals. The
study of mice was approved by the Albert Einstein College
of Medicine animal use committee. The FVB/N-Tg(MMTV-
PyVmT)Mul (PyMT) transgenic mice were kindly provided
by Dr. W.J. Muller (McGill University, Canada) and have
been described previously.10,25 Tg(Csf1r-Gfp)Hume
(MacGreen) mice have also been described previously.26
Male PyMT mice on an FVB background were bred to
homozygous MacGreen female mice on a mixed back-
ground to generate PyMT mice that produce tumors with
green fluorescent protein-labeled macrophages. All geno-
typing was done by PCR. Tumors were allowed to grow until
14 to 16 weeks to ensure late-stage carcinomas for TAM
isolation. Splenic macrophages were isolated from litter-
mates that do not carry the PyMT transgene.
Fluorescent Activated Cell Sorting
Flow cytometry was used for two purposes in this study:
to cell sort TAM and splenic macrophages and to immu-
nophenotype TAM. To identify phagocytic cells, 12 to
14-week-old PyMT/MacGreen female mice were lateral
tail-vein injected with 200 l 10 mg/ml 70,000 MW dex-
tran conjugated to the Texas Red fluorophore (Invitrogen,
Eugene, OR) resuspended in PBS. Two hours postinjec-
tion, animals were anesthetized with isoflurane and then
perfused i.c. with ice cold PBS. Following sacrifice, all
subsequent steps were performed at 4°C.
Isolating Macrophages
To avoid loss of surface markers, tumors and spleen were
minced and filtered four times through graded nylon fil-
ters, centrifuged at 1200 RPM for 5 minutes and then
resuspended in erythrocyte lysis buffer (Beckman-
Coulter, Marseille, France). Cells were washed three
times in nuclease-free PBS containing 2% bovine serum
albumin (PBS  2% BSA). Texas Red/EGFP double-
positive cells were sorted on a DakoCytomation MoFlo
High-Speed Cell Sorter (DakoCytomation, Inc, Fort Col-
lins, CO) at 23 p.s.i. into PBS  2% BSA.
Immunophenotyping TAMs
Tumor was minced in 1 ml of MEM medium before
adding Liberase at 0.028 Wunsch units/ml (Roche, Indi-
anapolis, IN) and DNase I at 20 g/ml (Sigma-Aldrich, St.
Louis, MO) as previously described.12 The mixture was
incubated for 30 minutes at 37°C under gentle agitation.
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Digestion was stopped with 0.5 ml fetal bovine serum
(FBS) and 100 l 0.5M EDTA pH 8.0. The suspension was
serially filtered as described above, erythrocyte lysis was
performed and cells were re-suspended in PBS  2% bo-
vine serum albumin (BSA) and incubated with Fc receptor
block using rat mAb anti-mouse CD16/CD32 (BD Bio-
sciences, San Jose, California) for 10 minutes. Subse-
quently cells were incubated with phycoerythrin (PE)-Cy5
conjugated anti-mouse F4/80, allophycocyanin-conjugated
anti-mouse Gr1, PE-Cy7 conjugated anti-mouse CD11b, or
PE-conjugated anti-mouse CD115/CSF1R (all eBioscience,
San Diego, California) for 40 minutes in the dark. Samples
were washed, fixed, and analyzed on DakoCytomation Mo-
Flo to detect enhanced green fluorescent protein (EGFP),
Texas Red, PE-Cy5, allophycocyanin, PE-Cy7, and PE.
Cytospin
Texas-Red/GFP and Texas-Red/GFP cells from tu-
mor cell suspension (as described for fluorescent-acti-
vated cell sorting) were sorted separately into PBS  2%
BSA. Sorted cells were pelleted and resuspended into
100 l PBS  2%BSA and cytospun onto Colorfrost/Plus
Microscope Slides (Fisher), followed by fixation in meth-
anol for 5 minutes. Slides were briefly air-dried then
stained with Accustain Wright-Giemsa Stain (Sigma-Al-
drich, St. Louis, MO) for 5 minutes. Excess stain was
rinsed with deionized water, dried, and mounted.
Immunohistochemistry
Primary tumors from late-stage tumor bearing animals
were dissected and frozen into optimal cutting tempera-
ture compound (Sakura Finetechnical, Tokyo, Japan).
Tissues were serially sectioned at 7 m by cryostat and
then prepared for immunohistochemistry. In brief, follow-
ing dehydration, sections were incubated with 3% hydro-
gen peroxide to block endogenous peroxidase activity.
Sections were blocked in normal rabbit serum for 10
minutes, followed by incubation with primary antibody for
1 hour at room temperature in a humidified chamber. The
following primary antibodies were used: rat mAb to
mouse F4/80 (Caltag Laboratories Inc., Burlingame, CA),
rat mAb to mouse Gr1 (BD Pharmingen, San Jose, CA),
and rat mAb to mouse clone 7/4 (Caltag Laboratories
Inc.) for macrophage, myeloid, and neutrophil detection,
respectively. Sections were next incubated in rabbit-anti-
rat secondary antibody for 40 minutes at room tempera-
ture in a humidified chamber. Specific reactivity was
detected using a peroxidase-based detection kit (Vector
Laboratories, Burlingame, CA) as previously described.10
Immunofluorescence
As previously described,27 tissue from MacGreen pri-
mary tumors with or without Texas-red dextran i.v. injec-
tion were dissected and fixed in 5% formalin in 20%
sucrose/PBS for 24 hours at 4°C followed by freezing and
sectioning. In the dark, sections were washed with deion-
ized water and blocked for 1 hour with 10% goat serum.
Sections were incubated in the dark at 4°C for 12 hours
with primary antibodies F4/80, Gr1 (listed above) and
anti-mouse CD115/CSF-1R (kindly provided by E.R. Stan-
ley, AECOM). Next, tissue sections were incubated with
Alexa Fluor 568 conjugated goat anti-rat antibody (In-
vitrogen, Carlsbad, CA) for 1 hour and then stained with
0.3 g/ml 4-6-diamidino-2-phenylindole (DAPI) for five
minutes followed by wash and mounting.
RNA Extraction, Amplification, and cDNA
Preparation
Total RNA was extracted from fluorescent-activated cell-
sorted TAMs and splenic macrophages using RNeasy Mi-
cro Kits (Qiagen, Valencia, CA) according to the manufac-
turer’s instruction. Amplification-grade DNase 1 treatment
was performed on the RNA elution column to remove po-
tential genomic DNA contamination. Approximate yields
were 150 ng; quality was determined using a nano-biosiz-
ing assay (Agilent Bioanalyzer; Agilent Technologies, Palo
Alto, CA).
Two hundred ng of RNA from samples was resuspended
into 11 l of RNase/DNase-free water, and a single round of
linear amplification was performed by the in vitro transcrip-
tion T7 promoter method as outlined by the manufacturer’s
protocol (Ambion’s Message Amp T7 Kit; Ambion, Austin,
TX). For microarray samples, a second round of linear am-
plification was performed with 200 ng of first round ampli-
fied material. At all steps, yield and quality were established
using spectrophotometry and an Agilent Bioanalyzer.
For samples to be used for microarray hybridization,
Superscript III (Invitrogen) reverse transcriptase was used
to prepare 5 g cDNA from amplified RNA. Random prim-
ers (Invitrogen) were used to prime reactions. Second-
strand cDNA synthesis was performed using E. coli DNA
ligase (Invitrogen), E. coli DNA polymerase 1 (Invitrogen),
and T4 DNA polymerase (Invitrogen). RNase H (Invitrogen)
treatment was additionally performed. The reaction was
stopped with 0.5 M/L EDTA and then purified using a PCR
purification kit (Qiagen) following manufacture’s protocol.
Samples were resuspended to approximately 200 ng/l.
Gene Expression Arrays
Five micrograms of double stranded cDNA from each
TAM and splenic macrophage sample were used for
gene expression array processing. The expression ar-
ray chip used contained 385,000 60-mer probes rep-
resenting 42,586 genes (average nine probes per tar-
get) (NimbleGen, Reykjavik, Iceland). A total of four
independent samples for each macrophage population
were prepared. At NimbleGen, quality and yield were
verified before DNA end-labeling, hybridization, and
scanning. Raw data files for each sample were normal-
ized, background-corrected and saved to logarithmic
scale using a Robust Multi-Array Analysis28 as imple-
mented by NimbleScan software, version 2.2.33. Normal-
ized data were analyzed and presented using R project
(http://www.R-project.org).29,30 All samples fulfilled qual-
ity criteria as determined by generation of pair-wise scat-
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ter, MA [the log ratio of intensities of two dyes used in the
hybridization, Cy3 and Cy5 (M), to the average of the log
intensities (A)] and expression density plots. Students’
two-tail t-tests were conducted between the TAM and
splenic macrophage samples for each transcript and
fold-change was determined. Transcripts whose abun-
dance were significantly altered (P  0.05) and an ab-
solute fold change greater than 2 were defined as differ-
entially regulated. Using these criteria, 831 transcripts
were called as down-regulated; 926 as up-regulated.
Significance Analysis of Microarray (SAM) analysis31 was
used for more stringent gene selection criteria. A delta
value of 1.74 called 462 significantly regulated tran-
scripts with a false discovery rate of 10%. Hierarchical
clustering32 was performed using MultiExperiment
Viewer version 4.1.01 (http://www.tm4.org).
Quantitative Real-Time PCR
For samples to be used for qrtPCR, Superscript III
(Invitrogen) reverse transcriptase was used to prepare
200 ng cDNA from amplified RNA. Random nonamers
(kind gift from Dr. Sumanta Goswami, Yeshiva Univer-
sity) were used to prime the reaction. Relative tran-
script abundance was detected by SybrGreen (Ap-
plied Biosystems, Foster City, CA) on the ABI 7900HT
thermal cycler using gene-specific primers (Table 1).
Gene expression was normalized to the housekeeping
gene, cyclophilin A (Ppia), and expressed values in
TAM relative to control splenic macrophages were de-
termined using the CT method.33
Bioinformatics
The Ingenuity Pathways Knowledge Base (IPA) was used to
identify enriched cellular and molecular functions among
differentially regulated transcripts. The Database for Anno-
tation, Visualization and Integrated Discovery (DAVID)
(http://david.abcc.ncifcrf.gov), the Gene Ontology Project,
(http://www.geneontology.org) and extensive literature re-
view was used for annotating regulated transcripts with a
gene ontology designation for pie-chart analysis. Fetal mac-
rophage gene expression data34 was downloaded and pro-
cessed as per a recent subsequent study.35 Microsoft Of-
fice Access 2007 was used to associate the data with TAM
gene expression data. Fisher’s exact t-test was used to
assess significance of association between datasets. On-
comine (http://www.oncomine.org), was used tomine human
breast cancer microarray data as previously described.36,37
Bone Marrow-Derived Murine Macrophage
Cultures
Bone marrow-derived murine macrophages (BMMs)
were prepared as previously described.38 Met-1fvb2 cells
Table 1. Quantitative rtPCR Primer Sequences
Symbol Name
Genbank
Accession Forward primer Reverse primer
ADAM8 A disintegrin and
metallopeptidase
domain 8
NM_007403 5-AGCCTGCCAGCTAAGAACAG-3 5-AACTGGGAGTGGTGAACTGG-3
APOE Apolipoprotein E BC083351 5-GGTTCGAGCCAATAGTGGAA-3 5-GGTGATGATGGGGTTGGTAG-3
ARG1 Arginase 1, liver NM_017134 5-CAGATATGCAGGGAGTCACC-3 5-CAGAAGAATGGAAGAGTCAG-3
C3AR1 Complement
component 3a
receptor 1
BC003728 5-ATTGGGACTGCTAGGCAATG-3 5-GGTGAGATGGAGGAACCAGA-3
CXCL4 Chemokine (C-X-C
motif) ligand 4
NM_019932 5-AGTCCTGAGCTGCTGCTTCT-3 5-GATCTCCATCGCTTTCTTCG-3
ECM1 Extracellular matrix
protein 1
NM_007899 5-CTCCGAGTTGACCACTCTGTAA-3 5-TCGTACACAGGGATGTCTTCTG-3
IL18 Interleukin 18 AY157834 5-GACTGGCTGTGACCCTCTCT-3 5-GATGAATTGGCGTGGAATCT-3
IRF4 Interferon regulatory
factor 4
NM_013674 5-AGCTCATGTGGAACCTCTGC-3 5-TGGTTCATCCAGCTGACTTG-3
ITGA6 Integrin, alpha 6 NM_008397 5-CAGGTTGTGGAACAGCACAT-3 5-GCGTGAGGGAGCTTGATATT-3
ITGB7 Integrin, beta 7 NM_013566 5-CAACTGGAAGCAGGACAACA-3 5-AGTCTGCTTCCCTGGTCAGA-3
LTBP3 Latent transforming
growth factor
beta binding
protein 3
NM_008520 5-TCCCCTTTCAGACCAGTGAG-3 5-CCTGGTCCTGTCTTCTCTCG-3
MIP1A Macrophage
inflammatory
protein 1 alpha
(chemokine C-C
motif ligand 3)
NM_011337 5-ACCAATGACACTCTGCAACCA-3 5-GATGAATTGGCGTGGAATCT-3
MMP12 Matrix
metallopeptidase 12
NM_008605 5-TGATGCAGCTGTCTTTGACC-3 5-CCTGGGAAGTGTGGAAAT-3
STAB1 Stabilin 1 NM_138672 5-GTTTGTCACTCACACACCCTGT-3 5-ATAGCGGCAGTCCAGAAGTATC-3
VEGFA Vascular
endothelial
growth factor
alpha
NM_009505 5-CAGGCTGCTGTAACGATGAA-3 5-GCATTCACATCTGCTGTGCT-3
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originally derived from mammary carcinomas in FVB/N-
Tg(MMTV-PyVmT)39 mice were a kind gift from Michael
Lisanti (Jefferson University, PA).
BMMs were seeded onto tissue culture plates and
allowed to adhere overnight in co-culture media (MEM;
10% FBS; 3  102 U/ml CSF-1). The next day, media was
either replaced with fresh co-culture media (BMM sam-
ple) or with sterile-filtered (0.22 m) co-culture media
conditioned with Met-1 cells for 24 hours (conditioned
media sample). Met-1 cells were also cultured separately
(Met-1 sample). Supernatants were collected and sterile-
filtered at 6 hours, 12 hours, and 24 hours then assayed
by enzyme linked immunosorbent assay (ELISA) for
VEGF and chemokine (C-C motif) ligand 3 (CCL3; R&D
Systems, Minneapolis, MN) per manufacturer’s protocol.
RNA was also isolated from all samples, extracted as
described above and used for qrtPCR.
Results
TAMs Can Be Identified and Sorted by Flow
Cytometry
In this study, TAMs were isolated from late-carcinoma
stage primary tumors of the transgenic polyoma middle T
oncoprotein mouse model of breast cancer (PyMT)25
crossed to the MacGreen animal in which EGFP is ex-
pressed under control of the Csf1r promoter to identify
myeloid-lineage cells.26 Recently, it has been reported
that mouse neutrophilic granulocytes express Csf1r
mRNA and are EGFP in the MacGreen animal.40 To
determine whether this was true in the tumor microenvi-
ronment, flow cytometric analysis was performed on
EGFP cells, and compared with unstained controls. Re-
sults indicate that these cells comprise a heterogeneous
population bearing mixed expression of the cell-surface
macrophage-specific markers, CSF-1R and F4/80 and
granulocyte-specific marker, Gr1 (Figure 1A, panels i, ii,
and iv). In contrast, all cells expressed the myeloid-spe-
cific marker, CD11b (Figure 1A, panel iii).
Previous work has indicated that the ability of macro-
phages to phagocytose fluorochrome-conjugated dex-
tran can be exploited for the identification of TAMs in
tumor-bearing animals and that a population of these
dextran TAMs promote carcinoma cell invasion.18 To
determine whether the dextran/EGFP cells comprised
a pure population of TAM, MacGreen tumor-bearing an-
imals were tail-vein injected with Texas-Red conjugated
70KD dextran two hours before sacrifice for further flow
cytometric analysis. Single-cell suspensions were me-
chanically prepared on ice and then stained with the
macrophage-specific antibody, F4/80 and the granulo-
cyte-specific antibody Gr1. Results indicate that while
EGFP cells from the MacGreen tumor were either F4/
80 or Gr1, dextran/EGFP double-positive cells were
enriched for F4/80 and not Gr1 positivity (Figure 1B). To
determine identity, dextran/EGFP and dextran/
EGFP cells were sorted by flow cytometry for cytospin
analysis. Whereas cells exhibiting polymorphonuclei
(typical of neutrophils) were abundant in dextran/
EGFP cells together with mononuclear cells, none were
identified in the dextran population (Figure 1C).
F4/80 TAMs Have a Distinct Distribution
Compared with Gr1 Cells
Flow cytometry results indicate F4/80 and Gr1 cells in
the tumor microenvironment differ in capacity to phago-
cytose dextran. Histologically, subpopulations of F4/80
TAMs are visible in the PyMT animal.11,41 These sub-
populations include TAM localized in stromal, hypoxic,
perivascular, and perinecrotic areas of late-stage tumors.
To determine how the distribution of Gr1 cells com-
pared with TAMs, serial frozen sections from late stage
Figure 1. Csf1r-EGFP expression and Texas-
Red conjugated 70kd dextran identify a pure
population of TAMs in vivo. A: Single-cell sus-
pensions were prepared from late-stage
MacGreen PyMT tumor bearing females and
stained for CD115 (external epitope of CSF-1R)
(i); F4/80 (ii); CD11b (iii); Gr1 (iv). Shaded gray
histograms indicate unstained EGFP control.
B: Single cell suspension of tumor from late-
stage MacGreen PyMT tumor I.V. injected with
texas-red conjugated dextran was prepared and
analyzed by flow cytometry. Dextran/EGFP
(top panel) and dextran/EGFP cells (bot-
tom panel) were separately analyzed for ex-
pression of F4/80 and Gr1. Average percentages
with SEM of three experiments are indicated.
Shown are representative plots. C: Cytospin fol-
lowed by Wright-Giemsa staining was per-
formed on dextran/EGFP and dextran/
EGFP cells sorted by flow cytometry.
Dextran/EGFP (top panels) cytospin con-
firms a pure population of mononuclear
phagocytes whereas dextran/EGFP (bot-
tom panels) reveal a heterogeneous population
of mononuclear and polymorphonuclear cells.
Scale bar 	 20 m.
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Figure 2. Localization of TAMs in PyMT Tumors. A: Immunohistochemistry was performed on serial frozen sections of late stage PyMT tumors. Negative irrelevant
control antibody (a). F4/80 staining illustrates localization of macrophages in the stroma and diffusely in the tumor islands (b). Gr-1 staining is more sparse and
restricted to stroma/peri-vascular areas of the tumor (c). Ly-6G staining is also restricted to stroma/peri-vascular areas of the tumor and appears to overlap with
Gr-1 staining as indicated by black arrows (d). Scale bar 	 50 m. B: Localization of dextran labeling (red) cells within MacGreen tumor. C: Localization of
CSF-1R (CD115) cells within MacGreen tumor. D: Localization of F4/80 cells within MacGreen tumor. E: Localization of Gr1 cells within MacGreen tumor. Inset
2 magnification of DAPI-stained nuclei in merged image. B left panels green (EGFP) channel, middle panels red channel, right panels merged image with
DAPI. Arrows indicate cells that are EGFP, but do not express cell-type specified markers. Scale bars 	 10 m.
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tumors were stained with both antibodies. As previously
reported, F4/80 cells were broadly distributed12,18 (Fig-
ure 2A, panel i, ii). In contrast Gr1 cells were not as
broadly distributed and appeared to be primarily re-
stricted to perivascular and stromal areas of the late
stage tumor (Figure 2A, panel iii). The Gr1 antibody re-
acts with both Ly-6C and Ly-6G protein. While Ly-6C is
present on cells of the mononuclear lineage,42 Ly-6G is
expressed predominantly on polymorphonuclear neutro-
phils.40 Consistent with the flow cytometry and cytospin
data, staining for Ly-6G on late-stage tumor overlaps with
staining for Gr1 in serial sections indicating further that
these Gr1 cells are distinct from the F4/80 TAMs
sorted for array studies (Figure 2A, panel iv).
Immunofluorescence was performed on late stage
MacGreen tumors to examine the co-localization of EGFP
with mature macrophage markers including pre-injected
dextran (Figure 2B), CSF-1R external epitope (Figure 2C)
and F4/80 (Figure 2D). Arrows indicate examples in each
panel where GFP expression fails to co-localize with the
queried macrophage marker. Consistent with flow-cytom-
etry the granulocyte marker, numerous EGFP cells co-
localized with the granulocyte marker, Gr1. Additionally,
GFP/Gr1 cells appear to have polymorphonuclei con-
sistent with the cytospin data and the identification of
these cells as neutrophils (Figure 2E and inset). All these
studies taken together indicate that the MacGreen mouse
labels neutrophils in tumor stroma, and that they are
abundant. However, this work also validates the use of a
marker, such as dextran, that is able to distinguish be-
tween F4/80 and Gr1 cells in our model system.
Henceforth in this study, TAMs are identified as dextran;
Csf1r-EGFP; F4/80; Gr1; Ly-6G; CD11b cells.
TAMs Exhibit a Unique Gene Expression Profile
Compared with Splenic Macrophages
Using EGFP expression from the Csf1r promoter and Texas
Red conjugated dextran as criteria for macrophage selec-
tion, TAMs were sorted from PyMT late stage tumor and
splenic macrophages with the same phenotype were
sorted from non-transgene bearing littermate controls. All
isolation steps were maintained at 4°C. RNA was extracted
from sorted populations and then validated for quantity and
quality before being linearly amplified to yield sufficient
material for array hybridization. Four biological repeats were
hybridized for each group (Figure 3A).
Hybridizations were normalized using the Robust Mul-
tichip Average method28 as described in the “Materials
and Methods” and log averages of normalized expres-
sion values for TAMs were plotted against values for
splenic macrophages (Figure 3B). The strong correlation
(r 	 0.9698) between the two groups indicates overall
Figure 3. TAM gene expression can be robustly
assayed by high-density oligoarrays and exhibit
a unique expression signature compared with
tissue splenic macrophages. A: Schematic of the
experimental procedure to compare TAMs ver-
sus splenic macrophages. B: Scatter plot. Aver-
age log expression of each queried transcript for
TAMs compared with splenic macrophages with
linear regression line overlaid (r 	 0.9698). C:
MA-plot. Log ratio of Cy3 expression (TAM) and
Cy5 expression (splenic macrophages) (M),
plotted against average of the log intensities (A).
Symmetry with respect to horizontal line indi-
cates lack of dye bias in array. D: Volcano plot.
Log fold change between groups versus signifi-
cance level as calculated by t-test (log10P val-
ue). Horizontal line marks P value 	 0.05. Ver-
tical lines mark log fold change less than or
greater than 1. With these criteria, 926 genes are
called as increased in TAMs compared with
splenic macrophages, and 831 genes are called
as decreased. E: SAM plot. Significance Analysis
of Microarrays with delta value of 1.74, false
discovery rate of 0.1. Called genes: 210 in-
creased expression in TAMs; 242 decreased ex-
pression; 8 not regulated by fold-change criteria.
F: Dendogram and hierarchical clustering.
Genes depicted are those called by SAM analy-
sis. Dark shaded boxes indicate low expression;
light shaded boxes indicate higher expression.
Clustering analysis robustly separate the TAM
samples from splenic macrophage samples.
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successful processing. No dye-bias was present as indi-
cated by the MA plot (Figure 3C), which plots the log ratio
(M) of the two dyes used in the hybridization, Cy3 and
Cy5, to the average of the log intensities (A).
A ‘volcano plot’ was generated to graphically repre-
sent transcripts of increased (log2 ratio greater than 1) or
decreased (log2 ratio less than 1) abundance in TAMs
as compared with splenic macrophages (Figure 3D).
Vertical lines demarcate these fold-change boundaries.
For each transcript, a student’s t-test was performed
between the TAM and splenic macrophages. These data
are plotted on the log10 transformed y axis. Transcripts
with a P value less than 0.05 (indicated by horizontal line
on the transformed axis at 1.36) were considered statis-
tically significant. Thus, those transcripts in the upper
left-hand panel (831 genes) were significantly of reduced
abundance in TAMs as compared with splenic macro-
phages and those transcripts in the upper right-hand
panel (926 genes) were of increased abundance.
While volcano plots are useful for visualizing data, in the
setting of high-density expression arrays, caution needs to
be exercised when applying a generally acceptable signif-
icance value to 
35,000 sets of data. The SAM method31
compares variance among all probes to the variance of
each individual probe to better predict significance on a
high-density platform. A user-defined delta value estab-
lishes cut-offs for transcripts significantly regulated as com-
pared with the overall population. For the arrays in this
study, a delta of 1.74 was used (Figure 3E). With this delta
value, 460 significant transcripts were called with a 10%
false discovery rate. For high-density expression arrays,
SAM is a more rigorous and stringent gene selection tool as
compared with t-tests and therefore the transcript abun-
dance of 460 regulated genes generated from this method
is used for further analysis (see Supplemental Table S1
available at http://ajp. amjpathol.org).
Figure 3F illustrates hierarchical clustering of these
460 transcripts called by SAM analysis. Notably, all four
TAM samples cluster together as did the splenic sam-
ples. This suggests that TAM exhibit a unique gene ex-
pression profile compared with splenic macrophages.
Using the less stringent gene selection criteria (ie, P 
Figure 4. Transcripts mediating immune func-
tion and tissue development are differentially
regulated in TAMs. Genes selected by SAM sub-
jected to bioinformatics analysis using IPA. A:
Most significantly enriched functional groups re-
lating to physiological system development and
function. B: Most significantly enriched groups
pertaining to molecular and cellular function.
Both panels include corresponding P values cal-
culated through IPA using right-tailed Fisher Ex-
act Test. C: Primary gene ontological classifica-
tion was designated for each differentially
regulated gene and a pie-chart was created to
visualize enriched gene ontologies in transcripts
decreased in abundance (left panel) and in-
creased abundance (right panel) in TAM. Leg-
end on right ascribes classifications. Percentages
associated with each wedge represent percent
enrichment in regulated gene population.
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0.05), the TAM samples remain clustering separately
from splenic macrophages (data not shown).
TAMs Express Increased Transcript Abundance
of Genes Regulating Immune Response,
Developmental Processes and Angiogenesis
Differentially expressed transcripts were uploaded to the
IPA database for exploration of enriched biological func-
tions in TAMs (Figure 4A). As previously reported, with a
high significance (P 	 3.2  1010) the ‘immune re-
sponse’ is differentially regulated between TAMs and
splenic macrophages. Additionally physiological pro-
cesses relating to ‘tissue development’ were significantly
regulated (P 	 2.3  106). Subcategories of tissue
development include ‘adhesion’ and ‘angiogenesis’ and
were also individually regulated with high significance
(P 	 2.3  106 and P 	 3.6  103, respectively). A
similar analysis was performed on the specific molecular
and cellular functions differentially regulated. Processes
such as ‘cell signaling’ and ‘posttranslational modifica-
tion’ were most significantly differentially expressed while
processes such as ‘cell-to-cell signaling’ and ‘cellular
movement’ were also enriched in the pooled abundance
of differentially regulated transcripts (Figure 4B).
To gain a better appreciation for functional processes
regulated in TAMs, the biological process gene ontolog-
ical classification for each transcript was determined
through the use of tools such as the Gene Ontology
Project and the DAVID, in addition to extensive literature
review. After establishing an ontological designation for
each differentially regulated transcript, two pie charts
were created to compare the results of enriched func-
tions in the up-regulated group (increased transcript
abundance in TAMs) to those in the down-regulated
group (decreased transcript abundance in TAMs) (Figure
4C). As suggested by the analysis performed on Ingenuity,
genes related to immune/defense response were abun-
dantly regulated, as were genes involved with developmen-
tal processes. Interestingly, while ‘angiogenesis’ was a sig-
nificantly regulated process as indicated through IPA when
analyzing the entire called 460-gene data set, pie chart
analysis indicates that angiogenesis-related genes were
uniformly of increased abundance in TAMs. Re-analyzing
the up- and down-regulated genes by IPA separately con-
firms this finding with the P value for ‘angiogenesis’ becom-
ing more significant in the up-regulated group (P 	 2.6 
104) and not significant in the down-regulated group.
In the decreased group, a number of immunoglobulin
and B-cell specific transcripts are called. This most likely
relates to a primary function of splenic macrophages—
engulfment and disposal of apoptotic leukocytes and
may also explain the number of apoptosis-related genes
regulated in this group.43 Considering the proportion of
apoptosis-related transcripts in the up-regulated group
this may suggest that TAMs in the late stage tumor main-
tain the ability to recognize and engulf apoptotic tumor
cells thus retaining a key function of innate immunity. This
is consistent with the selection of dextran phagocytosis
as a marker of macrophages in this analysis.
Taken together, the results from the bioinformatic pro-
cessing of regulated transcripts in TAM versus splenicmac-
rophages indicates that TAMs differentially regulate groups
of genes mediating immune response, tissue developmen-
tal processes and angiogenesis, in addition to other phys-
iologically relevant processes. These data suggest a func-
tional profile of TAMs as uniquely poised to perform tissue
trophic functions while at the same time maintaining certain
key roles in regulating innate immunology.
Quantitative Real-Time PCR Validates the Gene
Expression Array Data from Numerous
Ontological Clusters
Numerous genes identified through the microarrays were
validated by quantitative real-time PCR (qrtPCR) using rig-
orously designed and tested primers. Samples used for
qrtPCR were biological replicates to further validate the
Figure 5. Quantitative rtPCR validates gene ex-
pression array data from numerous ontological
clusters. Sixteen genes identified as differentially
regulated from arrays validated using qrtPCR
using separate biological repeats. All samples
were normalized to the housekeeping gene,
Pp1a. Data shown indicates relative expression
of TAMs (black bars) with respect to splenic
macrophages (gray bars), set to one. Gene sym-
bol abbreviations listed in Table 1.
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array data with independent repeats. While for array analy-
sis, it was necessary to use mRNA that had undergone two
rounds of amplification to obtain a sufficient quantity of
material, it was found that one round of amplification was
adequate to amplify sufficient material for qrtPCR. The rel-
ative expression of each gene for each sample was calcu-
lated with respect to the housekeeping gene, Pp1a. TAM
samples were normalized to the expression levels in splenic
macrophages (mean set at 1) and relative expressions of
TAMs compared with splenic macrophages for each gene
are indicated. All genes tested validated results from the
array. Results for sixteen genes up- and down-regulated
are shown in Figure 5. To verify bioinformatic results, ana-
lyzed genes were selected from various ontological clusters
and arranged accordingly. As the array data suggests, genes
regulating immune function, angiogenesis, cell adhesion, and
matrix degradation are transcriptionally regulated.
TAMs Secrete Numerous Factors Regulating
Tumor Angiogenesis
It has been established that TAMs have a significant role
in regulating tumor angiogenesis27,44,45 at least in part
through their ability to secrete VEGF.12 With the gene
expression array results, it was striking to note that a
number of other differentially regulated transcripts that
are ontologically called to have a role in regulating tumor
angiogenesis were also identified. Using IPA, the cellular
localization of all differentially regulated transcripts called
to have a role in angiogenesis was determined (Figure
6A). Most of the related proteins are localized to the
extracellular space suggesting the angiogenic regulatory
role that TAMs play in the tumor microenvironment. The
log ratio was superimposed atop the data and illustrates
that of 13 of 14 differentially regulated genes (P  0.05)
Figure 6. TAMs regulate tumor angiogenesis throughmultiple mediators.A:Differentially regulated transcripts (P 0.05) that were ascribed a role in angiogenesis (Gene
Ontology/IPA) were plotted on a schematic indicating cellular localization. Log ratio data were overlaid to indicate those genes of increased abundance in TAMs (red)
and those of decreased abundance (green). Stars label those results validated by qrtPCR. To determine whether these transcripts can be regulated in macrophages by
tumor cells, in vitro cultures were established between primary BMMs and Met-1 cells. B: ELISA for Mip1 (top) and VEGF (middle) is used to compare the validity of
the in vitro system to results from isolated TAMs. BMMs were cultured alone and treated with Met-1 cell conditioned media. Shown are representative results from three
experiments of collected supernatants at 6, 12, and 24 hours. (bottom) qrtPCR at 12 hours for BMMs treated with Met-1 conditioned media and control BMMs. Results
standardized to Pp1a housekeeping gene. Relative expression is normalized to that of the control BMM. Abbreviations: ADAMTS 1/8 (ADAM metallopeptidase with
thrombospondin type 1 motif, 1/8); ANG (angiogenin); CXCL4 (platelet factor 4 (chemokine (C-X-C motif) ligand 4); ECM1 (extracellular matrix protein 1); FN1
(fibronectin 1); MIP1A (chemokine (CC motif) ligand 3); MMP2 (matrix metallopeptidase 2); NRP2 (neuropilin 2); PTX3 (pentraxin-related gene); SERPINE1 (serpin
peptidase inhibitor, clade E, member 1); STAB1 (stabilin 1); SLURP1 (secreted LY6/PLAUR domain containing 1); VEGFA (vascular endothelial growth factor A).
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relating to angiogenesis are of increased transcript abun-
dance in TAMs compared with splenic macrophages.
One cellular function particularly enriched in TAMs was
cell-to-cell interaction. To ask the question of whether the
increased abundance of angiogenic-related tran-
scripts was related to interactions between the macro-
phages and carcinoma cell, cultures were set up such
that BMMs were plated overnight and then overlaid with
fresh media or media conditioned by Met-1 carcinoma cells
for 24 hours.
ELISAs for VEGF and CCL3/Mip1 were performed on
collected supernatants as a read-out for the validity of the
in vitro cultures. Both molecules emerged as an up-reg-
ulated chemokine on the gene expression arrays as well
as by qrtPCR. Increasing amounts of Mip1 protein was
found over time secreted into the supernatants of BMM’s
treated with Met-1 conditioned media. Negligible amounts
of Mip1 were secreted by BMMs or Met-1 cells alone
(Figure 6B i). Similar results were seen with VEGF, although
the carcinoma cells alone exhibited higher levels of basal
secretion than BMMs (Figure 5B ii). The results for VEGF
secretion are consistent with co-cultures between an ovar-
ian tumor cell line and differentiated peripheral blood
mononuclear cells as previously reported46 suggesting
conservation between tumor cell and macrophage
types used.
At 12 hours after introduction of conditioned medium,
RNA was isolated from BMMs treated with Met-1 cell-
conditioned media and control BMMs. Quantitative real
time PCR indicated that consistent with ELISA data,
Mip1, and VEGFA was increased in BMMs treated with
conditioned media. In addition, chemokine (C-X-C motif)
ligand 4 (CXCL4), another molecule shown to regulate
tumor angiogenesis, was increased in BMMs treated with
conditioned media. Stabilin 1 (Stab1) and extracellular ma-
trix protein 1 (ECM1) two other molecules identified in the
array analysis were not significantly up-regulated by the
tumor cell derived conditioned media (Figure 5b iii).
TAM Gene Expression Signature Significantly
Overlaps with Enriched Transcripts in Fetal
Macrophages
As indicated in Figure 4, the TAM gene expression sig-
nature is enriched for molecules affecting tissue morphol-
ogy and development. To further assess the significance
of this point, significantly regulated TAM transcripts (P 
Figure 7. Murine TAM signature overlaps with murine fetal macrophages and human breast cancer. A: Comparison of TAM differentially regulated transcripts (P
0.05) and top enriched transcripts identified in fetal macrophages35 indicates that the two macrophage populations are associated (P  0.001, Fisher’s Exact Test).
Overlapping transcripts between both groups and increased in TAMs are in blue and identified in Table 2. Overlapping transcripts decreased in TAMs are in red
and identified in Table 3. B:Oncomine-generated box-and-whiskers plots for Spp1/Osteopontin expression considering metastasis status (left) and 5-year survival
(right) using vandeVijver_Breast 2002 breast cancer gene expression dataset. P values generated using student’s t-test through Oncomine. C:Oncomine-generated
heat map from vandeVijver_Breast dataset. Left (S1) are from individuals with no evidence of metastatic disease and right (S2) with metastasis. Top correlated
transcripts to Spp1 expression are ranked on the right with associated coefficients. Boxed molecules were also identified as differentially expressed between TAMs
and splenic macrophages. All symbols are official gene symbols.
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0.05) were compared with the previously published gene
expression signature of macrophages isolated at day
15.5 postconception mouse embryos.34 Of the top 150
transcripts most enriched in fetal macrophages,35 26% of
molecules were also differentially regulated in TAMs (Fig-
ure 7A). Thirty-two overlapping molecules were in-
creased (Table 2) and 7 were decreased (Table 3) in
abundance in TAMs. Results indicate that there is a pos-
itive association between both macrophage populations
(Fisher’s Exact Test, P  0.001).
Osteopontin Expression Correlates with Multiple
TAM-Expressed Transcripts in Human Breast
Cancer
Osteopontin, or secreted phosphoprotein 1 (Spp1), is a
phosphorylated integrin-binding glycoprotein and one
example of a molecule enriched in fetal macrophages
and increased in TAMs (Figure 5 and Table 2). Spp1 is
known to be expressed by macrophages,47,48 including
TAMs.49 Moreover, Spp1 expression correlates with dis-
ease prognosis for numerous cancers including breast
cancer where it is associated with disease progression
and metastasis (reviewed50,51). This is evinced using the
Oncomine cancer microarray database36,37 to mine a
breast cancer gene expression study of 295 human
breast carcinoma biopsies (vandevijver_Breast)52 indi-
cating increased expression of Spp1 correlates with in-
creased coincident tumor metastasis and decreased
5-year survival (Figure 7B).
Spp1’s previous association with macrophage activity
and tumor progression, as well as access to the whole
genome, validated and pure TAM gene expression array
data reported here, rationalized our use of Oncomine to
determine transcripts co-expressed with Spp1 in the
vandevijver_Breast dataset. Using Oncomine, ranking of
Table 2. Enriched in Embryonic Phagocytes; Increased in TAMs
Symbol Gene name Log2 ratio P value
Msr2 Macrophage scavenger receptor 2 4.9161 2.22  105
Ccl12 Chemokine (C-C motif) ligand 12 4.1604 0.007088
Ccl2 Chemokine (C-C motif) ligand 2 4.054525 0.003846
C3ar1 Complement component 3a receptor 1 3.654725 0.000217
Ltc4s Leukotriene C4 synthase 3.6327 0.019116
Abca1 ATP-binding cassette, subfamily A (Abc1), member 1 3.561275 0.007704
Ccl7 Chemokine (C-C motif) ligand 7 3.42445 0.02399
Npl N-acetylneuraminate pyruvate lyase 3.407825 0.017164
Ms4a7 Membrane-spanning 4-domains, subfamily A, member 7 3.4012 0.007773
Gas6 Growth arrest specific 6 3.225975 0.033465
Cyr61 Cysteine rich protein 61 3.21085 0.024879
Hexb Hexosaminidase B 3.109725 0.016917
Spp1/Opn Secreted phosphoprotein 1 (osteopontin) 3.08975 0.000306
Apoe Apolipoprotein E 2.9758 0.014086
Gatm Glycine amidinotransferase 2.867175 0.025479
Anxa3 Annexin A3 2.6821 0.020122
Lgals9 Lectin, galactose binding, soluble 9 2.445575 0.001631
P2ry6 Pyrimidinergic receptor P2y, G-protein coupled, 6 2.43605 0.001127
Ccrl2 Chemokine (C-C motif) receptor-like 2 2.387875 0.016938
Adfp Adipose differentiation related protein 2.103775 0.012731
aMs4a6d Membrane-spanning 4-domains, subfamily A, member 6d 2.0592 0.038571
Fcgr1 Fc receptor, IgG, high affinity I 2.03215 0.019295
Gp49b Glycoprotein 49b 1.701525 0.008324
Ehd4 Eh-domain containing 4 1.68445 0.004299
Ier3 Immediate early response 3 1.61345 0.020651
Pros1 Protein S (alpha) 1.59845 0.017915
Ccr1 Chemokine (C-C motif) receptor 1 1.540675 0.039695
Itgam Integrin alpha M 1.135375 0.003645
Adcy7 Adenylate cyclase 7 1.04645 0.026588
Rgs1 Regulator of G-protein signaling 1 1.019575 0.020009
Dusp1 Dual specificity phosphatase 1 0.867275 0.044837
Sat1 Spermidine/spermine N1-acetyl transferase 1 0.784975 0.027386
Table 3. Enriched in Embryonic Phagocytes; Decreased in TAMs
Symbol Gene name Log2 ratio P value
Igh-6 Immunoglobulin heavy chain 6 (heavy chain of IgM) 3.985425 0.006788
Fcna Ficolin A 3.628125 0.049599
Cd163 Cd163 Antigen 2.73325 0.002958
Mgl1 Macrophage galactose N-acetyl-galactosamine specific lectin 1 1.91685 0.049294
S100A9 S100 calcium binding protein A9 (calgranulin B) 1.7435 0.04624
Ier2 Immediate early response 2 1.122525 0.001927
Amh Anti-mullerian hormone 0.4795 0.029225
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the most correlated transcripts revealed multiple mole-
cules that are co-expressed with Spp1 in malignant hu-
man breast tumors and also differentially expressed in
our TAMs, isolated from transgenic murine mammary
tumors (Figure 7C). Adam8 and Apoe, specifically are two
identified differentially regulated transcripts in TAMs that
were confirmed by qrtPCR (Figure 5) and found to be
co-expressed with SPP1 in the human study. Three other
molecules, solute carrier family 16, member a3 (Slc16a3),
cathepsin b (Catb) and apolipoprotein c1 (Apoc1) were
also differentially regulated between TAMs and splenic
macrophages (P  0.05) and co-expressed with the
human ortholog of SPP1.
Discussion
In experimental models of breast cancer, TAMs are
important components of the microenvironment that
promote tumor progression and enhance metastatic
potential. These activities contrast with the classical
immunological perspective, that they are important com-
ponents of the immune system due to their ability to
engulf and destroy harmful microbes, as well as for their
ability to present antigens to T-cells to initiate a more
professional assault on disease pathogens. This latter
view would suggest that macrophages would play an
important role in the rejection of tumors that were per-
ceived as foreign. Therefore, more insight into how mac-
rophages are not simply permissive, but facultative of
tumor growth in the tumor microenvironment has the po-
tential to shed insight into cancer and macrophage biol-
ogy and may expose new therapeutic opportunities. In
the experiments described in this paper we used high
density oligonucleotide arrays to dissect putative media-
tors of these trophic macrophage functions in the tumor
microenvironment.
Previously, experimental studies have demonstrated
functions for TAMs that have provided insight into how
macrophages facilitate tumor progression. TAMs have
been shown to regulate tumor angiogenesis,12,53,54 pro-
mote carcinoma cell motility and intravasation,18,55–57
promote matrix degradation,16,58 and modify the inflam-
matory context of the tumor microenvironment.22,59 Many
of these tissue trophic functions of TAMs are believed to
recapitulate functions of macrophages during develop-
ment. For example, a recent observation has been the
extent to which macrophages direct terminal end bud
morphogenesis in the mouse developing mammary gland
through promotion of collagen fibrillogenesis.20,21,60,61 It is
hypothesized that similar to their role in promoting “inva-
sion” of the terminal end bud into the surrounding mam-
mary fat pad, TAMs promote invasion of the leading edge
of a late-stage carcinoma during metastasis.15 While
these mechanisms have been well documented, the mo-
lecular basis of their control remains obscure, in particu-
lar how TAMs can be directed away from being immuno-
logically potent cells to those that potentiate tumor
progression to malignancy. In addition, growing evi-
dence of the contributions of other bone marrow cells
to tumor progression including myeloid derived sup-
pressor cells,62 mesenchymal stem cells,63 VEGFR1
hematopoietic progenitors64 and CCR1 myeloid cells65
underscores the necessity for rigorous identification of
cell population before initiating gene expression studies,
as demonstrated here.
In this context the macrophage biology field has re-
cently benefited from a number of gene expression mi-
croarray studies that have defined transcriptomes of
these cells from a range of tissue microenvironments. To
note, prudence is required during the analysis and inter-
pretation of any gene expression studies as results are
dependent on pure samples isolated under conditions
that minimize technically introduced gene expression
changes. This is especially true for macrophages that
readily adapt and react to new environments such as
during a common method of isolation that involves adhe-
sion to plastic surfaces.22 To overcome these problems
in this study we used flow cytometry to isolate transgeni-
cally (EGFP) labeled macrophages directed by the Csf1r
promoter from tissue maintained at 4°C that has not been
enzymatically processed nor requires adhesion steps for
purification. After an early observation that these
MacGreen animals have at least two populations of GFP-
labeled myeloid cells (40 and Figure 1), it was recognized
that another marker was needed to identify macro-
phages. It has been previously described in the lab that
the use of fluorochrome-labeled 70-kDa dextran could be
use to exploit the pathognomonic phagocytic nature of
macrophages.27 Considering the leakiness of immature
neovessels in the tumor microenvironment that are resis-
tant to complete clearing via PBS perfusion through the
right ventricle perimortem, using dextran to identify TAMs
also excludes monocytes from the sorted population.
Thus these steps ensure the purification of a true macro-
phage population with minimal perturbation and we de-
scribe a pure population of tissue macrophages that are
F4/80, CD11b and importantly, Gr1, thus fulfilling
attributes of a mature macrophage population.
TAMs as defined above were isolated from the trans-
genic PyMT mouse and an equivalent population of
splenic macrophages from littermate controls were iso-
lated and analyzed by high-density oligoarrays. Splenic
macrophages were chosen as a reference tissue macro-
phage population due to the feasibility of collecting large
numbers of cells using a similar protocol to that for the
TAM isolation and their defined immunological functions.
We chose not to use spleen from the same tumor-bearing
mice since primary tumors are known to affect the my-
eloid populations in spleen. Particularly there is recruit-
ment of myeloid cell suppressor cells that express the
Cd11b marker.66,67 However, these cells also express
Gr1 and are mostly granulocytic precursors66,67 and thus
would have been excluded by our selection criteria. Nev-
ertheless we wished to use an unperturbed population
that was in a resting state with selection for identical
markers as the TAMs. This rigorous selection also over-
comes much of the problem of splenic red and white pulp
macrophage heterogeneity and the abundance of den-
dritic cells in this organ. These cells have different immu-
nological responses and thus we chose mice that had not
been immunologically challenged.68,69 In future studies it
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will be interesting to compare the resting splenic macro-
phages with a similar population from tumor bearing
mice. In this study, hierarchical clustering demonstrated
that the two macrophage populations cluster separately.
This indicates that TAMs and splenic macrophages com-
prise separate populations based on gene expression.
Using the stringent SAM analysis, 460 transcripts were
identified as differentially regulated among the two pop-
ulations (see supplemental Table S1 available at http://
ajp.amjpathol.org). All results tested by qrtPCR in subse-
quent biological repeats validated the array.
Bioinformatic analysis of the microarray results indi-
cates that pro-tumor functions previously shown to be
characteristic of TAMs, are transcriptionally regulated
compared with splenic macrophages suggesting that
they are directed within the tumor microenvironment.
These include a number of differentially regulated tran-
scripts that could encode angiogenic molecules (Figure
4 and supplemental Table S1 available at http://ajp.
amjpathol.org). There is a similar enrichment identified for
transcripts known to be involved in cellular and tissue
developmental processes that are of increased abun-
dance in TAMs. Furthermore, comparison of the data put
forth here to previous expression arrays of macrophages
in the developing embryo indicate several genes that are
expressed (such as Spp1, Apoe, C3ar1, Trem2, and
Msr2) and differentially regulated in TAMs,34 Figure 5
and supplemental Table S1 available at http://ajp.
amjpathol.org). Previous TAM expression array studies
using 10K cDNA microarrays22 and cytokine bead ar-
rays23 were used to specifically examine regulated
genes of immunological significance. Numerous im-
mune-related transcripts were similarly regulated in this
study, for example, Tgfb, C3ar1, Cxcl16, Msr2, and Il18.
The recognition that much of this previous data derived
from different xenograft tumor models aligns here, with
TAMs derived from transgenic induced spontaneous
mammary tumors indicates the extent of conservation of
TAM activities between tumor types and further suggests
the extent of therapeutic benefit by targeting specific
TAM molecules.
While overall, the immunological suppressive pheno-
type of TAM is exhibited as previously ascribed to the
so-called M2 macrophages,70 in at least one case in
TAMs isolated from the PyMT animal a pro-inflammatory
chemokine, CCL3 (Mip1), was identified as being in-
creased in TAMs in contrast to previously published data.22
This fact was validated by qrtPCR and further by in vitro
culture studies in which BMMs were treated with media
conditioned by Met-1 cells, a tumor cell line derived from
the PyMT mouse39 by ELISA and qrtPCR. This suggests
that in fact, some pro-inflammatory functions of TAMs in
our model are maintained and illustrates a spectrum of
activities in macrophages, as opposed to the dichoto-
mous relationship suggested by the M1/M2 macrophage
distinction. Indeed we would contend that the strictures
of a binary description of macrophages as either M1 or
M2 preclude the reality of a wide diversity of phenotypes
displayed by macrophages in normal physiology and
within the tumor microenvironment. Our description within
a well-defined TAM population of elements of both M1
and M2 phenotypes emphasizes this point.
To examine further the angiogenic phenotype of TAMs,
pathway analysis using Ingenuity, was performed to iden-
tify those differentially regulated transcripts involved in
angiogenesis. As indicated in Figure 4, using the strin-
gent SAM criteria, angiogenesis-related transcripts are
differentially regulated—however to better visualize the
extent of this, pathway analysis was performed on those
transcripts that had a significance of P 0.05. Consistent
with the SAM criteria, most angiogenesis-related tran-
scripts differentially regulated were of increased abun-
dance in TAMs using the less stringent criteria. Further-
more, most of these transcripts are known secreted
proteins further indicating the role of TAMs in directing
angiogenesis in the tumor microenvironment (shown in
Figure 6A). The in vitro culture system described above
was used to evaluate secretion of the most well-charac-
terized pro-angiogenic cytokine, VEGF, and it was found
that while the Met-1 carcinoma cells have basal secretion
levels of VEGF, BMMs alone do not but can be stimulated
to produce VEGF when treated with Met-1 conditioned
media. Quantitative real time PCR showed a similar up-
regulation of another regulator of angiogenesis, CXCL4.
In contrast, other angiogenic regulators such as Stab1
and ECM1 were not differentially regulated simply in the
presence of Met-1 conditioned media suggesting that
other cues, besides carcinoma cells, within the tumor
microenvironment regulate these TAM phenotypes.
Because the bioinformatic analysis of differentially reg-
ulated TAM transcripts indicated a role for TAMs in tissue
development, the array results were compared with the
results of a recently published dataset for macrophages
isolated from mouse embryos at day 15.5 postconcep-
tion.34 In support of the bioinformatics, there was signif-
icant overlap between the two populations suggesting
conservation in function (Figure 7A). Ostepontin (Spp1)
was further investigated because of its recognized func-
tion in macrophage activity47,48 and tumor progres-
sion.50,51,71 There has been discussion in the literature of
the impact of macrophage-derived versus tumor-derived
Spp1 on tumor progression spurred by a study of 154
lymph node negative breast cancer patients.72 In this
study, the authors found that while Spp1 was identified in
infiltrating macrophages and lymphocytes in 70% of tu-
mor biopsies, Spp1 was only identified in the carcinoma
cells of 26% of tumor biopsies and this expression in
tumor cells correlated with worse disease prognosis. No
such association was identified in TAM expression. More
recently, it was demonstrated that systemic tumor-cell
derived Spp1 will alter the distribution of cells released
from the bone marrow, and consequently better promote
outgrowth of previously indolent tumors.73 However,
analysis of Spp1 against the van de Vijver breast cancer
study demonstrated similar expression of several other
differentially regulated TAM transcripts suggesting con-
served function and source. Several of these transcripts
including Slc16a3, Ctsb, Adam8, and Apoe, indepen-
dently correlate with worse disease outcome in the van
de Vijver study (data not shown) suggesting that similar
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to tumor-derived Spp1, TAM-derived Spp1 also contrib-
utes to worse disease outcome.
These final results are significant because they once
again demonstrate the validity of the transgenic PyMT
murine model of breast cancer for modeling human dis-
ease. Even further, the results demonstrate that individual
cell types can be studied in the context of a heteroge-
neous human tumor biopsy if a robust and validated gene
expression signature from a pure cell population is avail-
able for comparison. While this point has previously been
made in follicular lymphoma74 and human breast tu-
mors,75 work herein provides a novel example of gaining
insight into gene expression of human TAMs through
work in a mouse model of breast cancer.
Taken together, this work illustrates that within the tu-
mor microenvironment, macrophages display a gene ex-
pression signature capable of promoting tumor angio-
genesis, preventing optimal immune surveillance and
enhancing cellular processes supportive of tumor growth.
Whereas this regulation is directed in part by the tumor
cells, additional components of the tumor microenviron-
ment (such as fibroblasts, adipocytes, and hypoxia) may
also instruct macrophages to perform their functions
within the tumor microenvironment. Considering the di-
versity of cell types within a given tumor, it is critical to
rigorously identify and directly isolate well-characterized
cell types to investigate their contribution to tumor
growth. Using such an approach we have identified a
tumor associated macrophage expression signature that
will provide a valuable resource for further research into
the role of these cells in human malignancy.
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